Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BSX
stocks logo

BSX

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
4.89B
+18.78%
0.724
+16.81%
4.86B
+15.55%
0.700
+11.07%
5.10B
+11.82%
0.748
+6.79%
Estimates Revision
The market is revising Upward the revenue expectations for Boston Scientific Corporation (BSX) for FY2025, with the revenue forecasts being adjusted by 1.69% over the past three months. During the same period, the stock price has changed by -2.49%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.69%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.16%
In Past 3 Month
Stock Price
Go Down
down Image
-2.49%
In Past 3 Month
18 Analyst Rating
up Image0
Wall Street analysts forecast BSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BSX is 119.56 USD with a low forecast of 110.00 USD and a high forecast of 130.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
1 Hold
0 Sell
Strong Buy
up Image0
Current: 103.500
sliders
Low
110.00
Averages
119.56
High
130.00
up Image0
Current: 103.500
sliders
Low
110.00
Averages
119.56
High
130.00
Barclays
Matt Miksic
Buy
Maintains
$118 → $125
2025-04-25
Reason
Barclays
Matt Miksic
Price Target
$118 → $125
2025-04-25
Maintains
Buy
Reason
Barclays analyst Matt Miksic raised the firm's price target on Boston Scientific to $125 from $118 and keeps an Overweight rating on the shares. The firm says ADVANTAGE-AF's solid results for the use of Farawave and Farapoint in persistent atrial fibrillation should support FDA approval later this year.
Baird
David Rescott
Buy
Maintains
$115 → $120
2025-04-24
Reason
Baird
David Rescott
Price Target
$115 → $120
2025-04-24
Maintains
Buy
Reason
Baird raised the firm's price target on Boston Scientific to $120 from $115 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results and said they remain buyers of the shares and with the company firing on all cylinders, it has already offset tariffs.
Evercore ISI Group
Vijay Kumar
Buy
Maintains
$110 → $112
2025-04-24
Reason
Evercore ISI Group
Vijay Kumar
Price Target
$110 → $112
2025-04-24
Maintains
Buy
Reason
Truist Securities
Richard Newitter
Strong Buy
Maintains
$113 → $117
2025-04-24
Reason
Truist Securities
Richard Newitter
Price Target
$113 → $117
2025-04-24
Maintains
Strong Buy
Reason
Truist analyst Richard Newitter raised the firm's price target on Boston Scientific to $117 from $113 and keeps a Buy rating on the shares. The company delivered an "impressive" revenue and margin outperformance, while its guidance is absorbing the second-half tariff impact, the analyst tells investors in a research note.
RBC Capital
Shagun Singh
Buy
Maintains
$116 → $120
2025-04-24
Reason
RBC Capital
Shagun Singh
Price Target
$116 → $120
2025-04-24
Maintains
Buy
Reason
RBC Capital raised the firm's price target on Boston Scientific to $120 from $116 and keeps an Outperform rating on the shares. The company reported impressive Q1 results, and the firm sees Boston Scientific as among the highest performing MedTech large-caps this year and beyond, the analyst tells investors in a research note.
Needham
Mike Matson
Strong Buy
Maintains
$113 → $115
2025-04-24
Reason
Needham
Mike Matson
Price Target
$113 → $115
2025-04-24
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Boston Scientific Corp (BSX.N) is 34.93, compared to its 5-year average forward P/E of 26.59. For a more detailed relative valuation and DCF analysis to assess Boston Scientific Corp 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PE
26.59
Current PE
34.93
Overvalued PE
30.69
Undervalued PE
22.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
20.90
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
24.14
Undervalued EV/EBITDA
17.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.39
Current PS
0.00
Overvalued PS
6.42
Undervalued PS
4.37

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

BSX News & Events

Events Timeline

(ET)
2025-04-24
15:43:50
Boston Scientific says second phase of ADVANTAGE AF study met primary endpoints
select
2025-04-23 (ET)
2025-04-23
06:50:48
Boston Scientific CFO Dan Brennan to retire, Jon Monson to succeed
select
2025-04-23
06:41:38
Boston Scientific raises FY25 adjusted EPS view to $2.87-$2.94 from $2.80-$2.87
select
Sign Up For More Events
Sign Up For More Events

News

Preview
3.0
05-12NASDAQ.COM
Validea Detailed Fundamental Analysis - BSX

  • Boston Scientific Corp Analysis: Boston Scientific Corp (BSX) receives a high rating of 68% from Validea's Multi-Factor Investor model, which focuses on low volatility stocks with strong momentum and high net payout yields, indicating moderate interest in the stock.

  • Pim van Vliet's Investment Strategy: Pim van Vliet, head of Conservative Equities at Robeco Asset Management, emphasizes that low volatility stocks can outperform high volatility ones with less risk, as detailed in his research and book "High Returns From Low Risk."

Preview
4.0
05-07WSJ
Road Warriors, Beware: Business Travel Takes a Hit

  • Travel Budget Cuts: Companies are tightening travel budgets after global business travel spending exceeded pre-pandemic levels in 2024, preparing for potential economic downturns.

  • Shift to Virtual Meetings: Employees may face increased scrutiny on travel expenses and a shift towards more Zoom calls instead of in-person meetings.

Preview
3.0
05-07NASDAQ.COM
BSX Factor-Based Stock Analysis

  • Boston Scientific Corp Analysis: Boston Scientific Corp (BSX) receives a high rating of 68% from Validea's Multi-Factor Investor model, which focuses on low volatility stocks with strong momentum and high net payout yields, indicating moderate interest in the stock.

  • Pim van Vliet's Investment Strategy: Pim van Vliet, head of Conservative Equities at Robeco Asset Management, emphasizes that low volatility stocks can outperform high volatility ones with less risk, as detailed in his research and book "High Returns From Low Risk."

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Boston Scientific Corp (BSX) stock price today?

The current price of BSX is 103.5 USD — it has increased 0.61 % in the last trading day.

arrow icon

What is Boston Scientific Corp (BSX)'s business?

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company’s segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. The Cardiovascular segment includes Cardiology and Peripheral Interventions. The Company's Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions.

arrow icon

What is the price predicton of BSX Stock?

Wall Street analysts forecast BSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BSX is 119.56 USD with a low forecast of 110.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Boston Scientific Corp (BSX)'s revenue for the last quarter?

Boston Scientific Corp revenue for the last quarter amounts to 4.66B USD, increased 20.93 % YoY.

arrow icon

What is Boston Scientific Corp (BSX)'s earnings per share (EPS) for the last quarter?

Boston Scientific Corp. EPS for the last quarter amounts to 0.45 USD, increased 36.36 % YoY.

arrow icon

What changes have occurred in the market's expectations for Boston Scientific Corp (BSX)'s fundamentals?

The market is revising Upward the revenue expectations for Boston Scientific Corporation (BSX) for FY2025, with the revenue forecasts being adjusted by 1.69% over the past three months. During the same period, the stock price has changed by -2.49%.
arrow icon

How many employees does Boston Scientific Corp (BSX). have?

Boston Scientific Corp (BSX) has 48000 emplpoyees as of May 14 2025.

arrow icon

What is Boston Scientific Corp (BSX) market cap?

Today BSX has the market capitalization of 152.19B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free